Rail Vision (NASDAQ:RVSN) reported quarterly losses of $(0.19) per share. This is a 20.83 percent increase over losses of $(0.24) per share from the same period last year.
HC Wainwright & Co. Reiterates Buy on DICE Therapeutics, Maintains $60 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates DICE Therapeutics (NASDAQ:DICE) with a Buy and maintains $60 price target.